SCIB1 or iSCIB1+ DNA vaccine clinical trials

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

This study looks at new cancer vaccines, SCIB1 and iSCIB1+, for advanced skin cancer (melanoma). They are being tested with standard treatments (nivolumab/ipilimumab or pembrolizumab) to see if they are safe and can help these treatments work better or for longer.